← Back to Search

JAK Inhibitor

PF-06700841 for Scarring Alopecia

Phase 2
Waitlist Available
Led By Emma Guttman, MD
Research Sponsored by Emma Guttman
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12, week 24 and week 48
Awards & highlights

Summary

This trial tests a new drug, PF-06700841, for people with scarring alopecia, a condition where hair follicles are destroyed and cannot regrow hair. The drug blocks specific enzymes to reduce inflammation and prevent scarring. The study will also collect skin and blood samples to understand how the drug affects the disease.

Eligible Conditions
  • Scarring Alopecia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12, week 24 and week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12, week 24 and week 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes from baseline in CCL5 gene expression level in response to PF-06700841
Changes from baseline in CXCR3 gene expression level in response to PF-06700841
Incidence and Severity of Treatment-Emergent adverse events
Secondary study objectives
Change in Physician Global Assessment of Improvement (PGA-I)
Change in the Dermatology Quality of Life Index (DLQI)
Changes from baseline in CXCL10 gene expression level in response to PF-06700841
+7 more

Side effects data

From 2022 Phase 2 trial • 194 Patients • NCT04092452
11%
Headache
9%
Acne
6%
Urinary tract infection
2%
Cellulitis
2%
Suicidal ideation
2%
Nausea
2%
Hidradenitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
PF-06650833 400mg QD
PF-06700841 45mg QD
PF-06826647 400mg QD

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-06700841Experimental Treatment1 Intervention
tablets containing active drug (a combined TYK/JAK inhibitor)
Group II: PlaceboPlacebo Group1 Intervention
Tablets without active ingredients
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-06700841
2018
Completed Phase 2
~2120

Find a Location

Who is running the clinical trial?

Emma GuttmanLead Sponsor
3 Previous Clinical Trials
140 Total Patients Enrolled
PfizerIndustry Sponsor
4,625 Previous Clinical Trials
14,284,144 Total Patients Enrolled
Emma Guttman, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
1 Previous Clinical Trials
930 Total Patients Enrolled
~12 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top